{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=12",
    "query": {
      "condition": "Metastatic Adenocarcinoma of the Pancreas",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 429,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Pancreas&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T09:35:04.641Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04666740",
      "title": "A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Homologous Recombination Deficiency (HRD)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2020-12-18",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 7,
      "location_summary": "Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more",
      "locations": [
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666740"
    },
    {
      "nct_id": "NCT04229004",
      "title": "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Pancreatic Cancer",
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine combined with nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Dose -mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Drug: Dose -SM-88",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pancreatic Cancer Action Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 502,
      "start_date": "2020-01-31",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 25,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04229004"
    },
    {
      "nct_id": "NCT00126633",
      "title": "Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2004-04",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2012-09-17",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00126633"
    },
    {
      "nct_id": "NCT02575508",
      "title": "Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Rectal Adenocarcinoma",
        "Stage III Pancreatic Cancer",
        "Stage IIIA Colon Cancer",
        "Stage IIIA Rectal Cancer",
        "Stage IIIB Colon Cancer",
        "Stage IIIB Rectal Cancer",
        "Stage IIIC Colon Cancer",
        "Stage IIIC Rectal Cancer",
        "Stage IV Pancreatic Cancer",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "pan FGFR Kinase Inhibitor BGJ398",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-05-20",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02575508"
    },
    {
      "nct_id": "NCT02568267",
      "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cholangiocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Neoplasms",
        "Lymphoma, Large-Cell, Anaplastic",
        "Melanoma",
        "Neuroendocrine Tumors",
        "Non-Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Papillary Thyroid Cancer",
        "Primary Brain Tumors",
        "Renal Cell Carcinoma",
        "Sarcomas",
        "Salivary Gland Cancers",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 534,
      "start_date": "2015-11-19",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02568267"
    },
    {
      "nct_id": "NCT05736731",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Solid Tumor",
        "Pancreatic Cancer",
        "Pancreatic Neoplasms",
        "Pancreas Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "NSCLC",
        "NSCLC, Recurrent",
        "Colorectal Cancer",
        "Colorectal Neoplasms",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colorectal Cancer Metastatic",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "A2B530",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT-Onco with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-04-28",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05736731"
    },
    {
      "nct_id": "NCT07621718",
      "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Cancer Metastatic",
        "PDAC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Pancreatic Adenocarcinoma Metastatic",
        "Pancreatic Adenocarcinoma",
        "Pancreatic Adenosquamous Carcinoma"
      ],
      "interventions": [
        {
          "name": "Zoldonrasib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin (Calcium Folinate)",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (GEM)",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 670,
      "start_date": "2026-05-22",
      "completion_date": "2030-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07621718"
    },
    {
      "nct_id": "NCT04809766",
      "title": "Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Stage IV Pancreatic Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Autologous Mesothelin-specific TCR-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2021-12-14",
      "completion_date": "2025-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04809766"
    },
    {
      "nct_id": "NCT05068752",
      "title": "Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreas Cancer"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HonorHealth Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-10-28",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05068752"
    },
    {
      "nct_id": "NCT06999187",
      "title": "A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "Castrate Resistant Prostate Cancer",
        "Pancreatic Ductal Adenocarcinoma",
        "Head-and-neck Squamous Cell Carcinoma",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "DR-0202",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dren Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2025-06-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-15T09:35:04.641Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06999187"
    }
  ]
}